When does the Entyvio (vedolizumab) patent expire?
Entyvio’s patent expiry depends on the specific patent listed for vedolizumab and the form of protection involved (for example, method-of-use vs. composition-of-matter, and whether there are regulatory exclusivity periods on top of patents). Patent-watch resources track these dates by individual patent family, since different claims can expire at different times.
For a running list of relevant vedolizumab patents and their expiration timelines, see DrugPatentWatch: https://www.drugpatentwatch.com/p/entiyvio/ (search “Entyvio” on the site if the URL changes) [1].
Do patents expire on the same date as exclusivity?
Not necessarily. Drug market protection can include both patent terms and regulatory exclusivities. Even if a patent expires, other patents or regulatory exclusivities can still keep generic or biosimilar competition off the market until their own protection periods end. That is why patent-watch pages break out protection by specific patent numbers and dates rather than giving one single “expiration” date [1].
Could a biosimilar enter before all patents for Entyvio expire?
Yes. If earlier-expiring patents clear first (or if a competitor designs around certain claims), a biosimilar can potentially launch while other later-expiring patents remain in force. The exact outcome depends on how the patent portfolio is structured and what claims remain enforceable as each patent expires [1].
What to check if you want the most exact “expiration” date
If you’re trying to pin down the date relevant to competition or generic/biosimilar entry, use the patent-watch list and focus on:
- The latest-expiring patents in the asserted portfolio for the product
- Whether any patents are method-of-use vs. composition-of-matter
- Whether there are legal stays or settlements affecting launch timing (these don’t change patent expiry, but they can change real-world entry timing) [1]
Who makes Entyvio and what does that imply for patent tracking?
Entyvio is marketed in the US by Takeda (via its affiliates). Patent entries are still tracked at the molecule/product level, so the key is the vedolizumab patent portfolio and associated claim types rather than the brand owner alone [1].
Sources:
[1] https://www.drugpatentwatch.com/p/entiyvio/